Aripiprazole Lauroxil: A Review in Schizophrenia

James E Frampton
Compliance with Ethical Standards Funding: The preparation of this review was not supported by any external funding. Conflicts of interest: James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Additional information about this Adis Drug Review can be found here. Abstract Aripiprazole lauroxil long-acting injectable (LAI) [Aristada®] is an intramuscularly administered, extended-release prodrug of aripiprazole, an established atypical antipsychotic agent that, in terms...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.